Welcome to our dedicated page for Rapid Dose Thera news (Ticker: RDTCF), a resource for investors and traders seeking the latest updates and insights on Rapid Dose Thera stock.
Rapid Dose Therapeutics Corp. (RDTCF) is a biotechnology innovator advancing drug delivery platform QuickStrip™, an oral thin film technology with applications across pharmaceuticals, nutraceuticals, and clinical research. This page provides authorized updates about corporate developments and scientific milestones.
Investors and researchers will find verified information on clinical trial progress, regulatory updates, and strategic partnerships. Our curated collection includes press releases about QuickStrip™ applications in pain management studies, dental anesthesia innovations, and bioavailability research collaborations.
Key content categories include financial disclosures, product development announcements, intellectual property updates, and clinical research findings. All materials are sourced directly from company filings and authorized communications to ensure accuracy.
Bookmark this page for streamlined access to RDTCF's latest advancements in transmucosal drug delivery technology. Check regularly for updates on FDA submissions, partnership expansions, and new therapeutic applications of the QuickStrip™ platform.
Rapid Dose Therapeutics (RDTCF) has provided an update on its collaboration with the University of Regina's Faculty of Kinesiology & Health Studies for an NFL-funded medical cannabis research project. The study focuses on examining cannabinoids' effects on sport concussion and pain management.
The project has entered the clinical trial phase, investigating the bioavailability of CBD through RDT's QuickStrip™ sublingual delivery system compared to standard oral formulation. The randomized, two-arm clinical study, approved by Health Canada, involves researchers from the Universities of Regina, Saskatchewan, and British Columbia.
The study specifically examines the pharmacokinetic parameters of non-psychoactive cannabidiol (CBD) and its metabolites in healthy young adults. The QuickStrip™ technology consists of rectangular oral thin films infused with cannabis extract that dissolve under the tongue, releasing the compound directly into the mucus membranes.
Rapid Dose Therapeutics (CSE: DOSE) has announced its participation in major dental tradeshows across Canada to showcase XyliStrip, an oral dissolving thin film strip powered by QuickStrip technology. The product is designed to address dry mouth (Xerostomia), which affects over 20% of the population and is one of North America's fastest-growing oral health problems.
XyliStrip utilizes RDT's proprietary sublingual thin film strip technology that can be infused with various active ingredients, including Nutraceuticals, Pharmaceuticals, Cannabis, and Nicotine, for rapid bloodstream delivery. The company will present at seven major dental events from April to October 2025, including the Women In Dentistry Symposium, Ontario Society of Periodontists Spring Meeting, and the American Association of Periodontology & Canadian Association of Periodontists Joint Meeting.
Rapid Dose Therapeutics (CSE: DOSE) has announced plans to issue common shares to satisfy the quarterly interest payment due March 31, 2025, on its secured convertible notes. The company will issue 463,716 common shares at $0.20 per share, totaling $92,745.22 in accrued interest.
The notes, issued in 2023 through a private placement financing of $3,134,445, carry a 12% annual interest rate and mature on November 30, 2025. The financing included units priced at $1.00, each comprising notes and five common share purchase warrants, resulting in 15,672,225 warrants issued.
Additionally, RDT has received an extension from the CSE until April 24, 2025, to complete its previously announced shares-for-debt transaction. This transaction involves issuing up to 1,600,000 common shares at $0.25 per share to settle approximately $400,000 in outstanding accounts payable with creditors.
Rapid Dose Therapeutics Corp (CSE: DOSE) has announced plans for an equity private placement financing to raise up to $5,000,000 in gross proceeds. The financing will consist of up to 20,833,333 common shares priced at $0.24 per share.
The company has engaged Meadowbank Asset Management Inc. as the agent, who will receive a 1% cash commission on proceeds from investors they introduce, plus agent warrants equal to 6% of shares issued to their referred investors. Each agent warrant will be exercisable at $0.33 per share for two years.
The proceeds will be used for debt retirement, research and development, capital expansion, and working capital. The financing may close in multiple tranches, with securities subject to a four-month hold period.
Rapid Dose Therapeutics (CSE: DOSE) has expanded its collaboration with an unnamed international company in oral nicotine products through an exclusive pre-commercialization agreement extending to June 19, 2025. The agreement involves RDT providing project management and product development services for a monthly fee of USD$120,000.
The collaboration, which began in December 2022, focuses on finalizing innovative, market-ready products for launch in 2025. Key development areas include formulation optimization, packaging enhancement, consumer studies, product benchmarking, and regulatory documentation preparation. The partnership leverages RDT's proprietary QuickStrip™ Oral Thin Film (OTF) technology to develop next-generation smoke-free alternatives.
Rapid Dose Therapeutics (CSE: DOSE) has received an extension from the Canadian Securities Exchange for its previously announced debt settlement transaction. The extension allows the company to close the Shares for Debt Transaction by March 10, 2025. The transaction involves issuing up to 1,600,000 common shares at $0.25 per share to creditors in exchange for canceling approximately $400,000 in outstanding accounts payable.
Additionally, the company announced it will not proceed with the previously disclosed private placement of units (shares and warrants) worth up to $6,000,000 at this time.
Rapid Dose Therapeutics (CSE: DOSE) has completed a shares for debt transaction with its non-management directors. The company issued 681,815 Debt Shares at $0.22 per share to settle an aggregate debt of $150,000 in directors' fees.
The debt comprised of $10,000 owed to each of the five directors for the fiscal quarters ended May 31, August 31, and November 30, 2024. The share price was set at the closing market price on December 31, 2024. The issued shares are subject to a four-month hold period.
This transaction aims to improve the company's financial position by reducing existing liabilities. The issuance constitutes a related party transaction under MI 61-101, with the company utilizing exemptions from valuation and minority shareholder approval requirements.
Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due December 31, 2024, on its secured convertible notes. The company will issue 430,930 common shares at $0.22 per share to cover $94,806.23 in accrued interest.
This share issuance stems from the company's previous private placement financing, where RDT issued $3,134,445 in principal amount of Notes and 15,672,225 Warrants in 2023. The Notes, maturing on November 30, 2025, carry a 12.0% annual interest rate, payable quarterly in common shares. The share price is determined by the closing market price on the CSE at each quarter's end.
The newly issued shares will be subject to a four-month and one-day hold period from their issue date, expected no later than January 15, 2025.
Rapid Dose Therapeutics (CSE: DOSE) has announced a shares-for-debt transaction with its five non-management directors to settle outstanding director fees. Each director is owed $10,000 for three fiscal quarters (May 31, August 31, and November 30, 2024), totaling an aggregate debt of $150,000.
The company will issue common shares at a price equal to the closing market price on December 31, 2024, with expected issuance around January 15, 2025. The shares will be subject to a four-month hold period. This transaction aims to improve RDT's financial position by reducing existing liabilities. No new control person will be created through this transaction.
Rapid Dose Therapeutics (CSE: DOSE) has announced a proposed equity private placement financing aiming to raise up to $6,000,000 through the issuance of up to 24,000,000 units at $0.25 per unit. Each unit includes one common share and one warrant exercisable at $0.33 for two years.
The company plans to use the proceeds for debt retirement, research and development, capital expansion, and working capital. Meadowbank Asset Management will serve as the agent, receiving a 1% cash commission and 6% in agent warrants.
Additionally, RDT plans to settle up to $400,000 in debt through the issuance of up to 1,600,000 common shares at a minimum price of $0.25 per share to improve its financial position.
FAQ
What is the current stock price of Rapid Dose Thera (RDTCF)?
What is the market cap of Rapid Dose Thera (RDTCF)?
